<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990427</url>
  </required_header>
  <id_info>
    <org_study_id>CLBS201-P01</org_study_id>
    <nct_id>NCT04990427</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study Evaluating the Safety and Efficacy of CLBS201 in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CLBS201 Autologous Peripheral Blood-Derived CD34+ Cells in Subjects With Chronic Kidney Disease and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caladrius Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Caladrius Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLBS201 will be studied to evaluate the safety, tolerability, and therapeutic effect in&#xD;
      subjects with CKD and Type 2 DM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion of patients with a treatment-emergent serious adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in eGFR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine (SCr)</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in SCr from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>CLBS201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLBS201 will be administered in an open-label fashion into the renal arteries in 6 subjects and randomized in up to 24 subjects via intra-arterial infusion and the patients observed for 12 months after infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be randomly administered into the renal arteries in up to 16 subjects via intra-arterial infusion and the patients observed for 12 months after infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLBS201</intervention_name>
    <description>1 x 10^6 to 300 x 10^6 autologous CD34+ cells</description>
    <arm_group_label>CLBS201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Isotonic solution with autologous serum and human serum albumin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged 18 to 75 years&#xD;
&#xD;
          2. Documented diagnosis of type 2 diabetes&#xD;
&#xD;
          3. eGFR of 30 to &lt;45 mL/min/1.73m at the screening visit.&#xD;
&#xD;
          4. UACR 300 mg/g to ≤ 5000 mg/g&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hemoglobin &lt; 10 g/dL&#xD;
&#xD;
          2. Hemoglobin A1c ≥8% at the time of screening&#xD;
&#xD;
          3. Acute kidney injury within 6 months prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William K Sietsema</last_name>
    <role>Study Director</role>
    <affiliation>Vice President, Global Regulatory Affairs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Swetha Mandava</last_name>
    <phone>9732049467</phone>
    <email>smandava@caladrius.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Kotynski</last_name>
    <phone>908-420-5753</phone>
    <email>ckotynski@caladrius.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Diabetic Kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

